Immune Checkpoint Inhibitors and Lupus Erythematosus
Immune checkpoint inhibitors (ICIs) are the standard of care for a growing number of malignancies. Unfortunately, they are associated with a broad range of unique toxicities that mimic the presentations of primary autoimmune conditions. These adverse events are termed immune-related adverse events (...
Salvato in:
| Autori principali: | , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
MDPI AG
2024-02-01
|
| Serie: | Pharmaceuticals |
| Soggetti: | |
| Accesso online: | https://www.mdpi.com/1424-8247/17/2/252 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|